Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A

SSZSE:300026
3.01
CNY
-0.04
(-1.31%)
9.76BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.84
1.13
1.25
1.29
1.12
1.4
1.74
2.15
2.57
2.24
2.05
2.69
- -
- -
Basic EPS, GAAP
0.14
0.18
0.2
0.22
0.15
0.07
0.14
0.19
0.23
0.21
0.17
0.01
- -
- -
Free Cash Flow per Basic Share
0.01
-0.01
-0.04
0.01
0.12
0.03
-0.13
-0.12
-0.1
-0.01
0.4
0.31
- -
- -
Dividend per Share
0.01
0.02
0.03
0.02
0.03
0.02
0.02
0.06
0.05
0.06
0.05
0.06
- -
0.01
Book Value per Share
0.67
0.85
1.75
1.97
2.11
2.13
2.26
2.39
2.59
2.76
2.9
2.88
- -
2.85
Tangible Book Value per Share
0.63
0.78
1.23
1.43
1.59
1.68
1.83
1.96
2.16
2.32
2.44
2.44
- -
2.45
Basic Weighted Avg Shares
2,505
2,530
2,675
2,993
3,005
3,011
2,875
3,018
2,988
2,973
2,980
2,147
1,850
3,075
Sales/Revenue/Turnover
2,097
2,864
3,348
3,867
3,374
4,224
5,003
6,488
7,671
6,650
6,109
5,783
- -
- -
Operating Margin (%)
19.24
17.42
17.89
19.54
19.69
14.58
12.96
12.68
14.79
12.74
10.45
4.52
- -
- -
Depreciation Expense
43
50
57
95
109
131
156
190
261
307
346
347
- -
- -
Net Income, GAAP
340
447
535
659
451
211
403
573
687
624
507
21
- -
- -
Effective Tax Rate (%)
14.96
13.56
13.31
15.63
22.28
33.37
15.69
18.11
21.46
13.28
17.35
57.49
- -
- -
Profit Margin (%)
16.19
15.61
15.98
17.03
13.36
4.99
8.05
8.84
8.96
9.39
8.29
0.37
- -
- -
Working Capital
834
1,166
2,499
2,697
2,935
3,075
3,094
3,337
4,748
4,707
5,155
4,528
- -
4,473
LT Debt
19
- -
5
- -
- -
- -
45
470
1,525
1,423
1,317
640
- -
209
Total Equity
1,703
2,204
5,290
6,039
6,509
6,576
7,070
7,392
7,952
8,463
8,868
8,799
- -
8,687
Return on Invested Capital (%)
19.74
19.88
12.48
10.22
6.16
2.9
5.82
6.77
7.55
6.19
3.99
0.16
- -
- -
Return on Capital (%)
20.93
21.6
13.52
11.03
6.99
3.14
5.7
7.59
7.99
6.72
5.37
0.39
- -
- -
Return on Common Equity (%)
22.14
23.03
14.34
11.76
7.34
3.3
6.1
8.2
9.18
7.77
5.96
0.25
- -
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
180
147
139
LT Borrowings
239
144
132
LT Finance Leases
97
96
77
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,004
3,004
3,004
Market Capitalization
10,635
8,712
9,764

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,735
5,767
5,597
Cash, Cash Equivalents & STI
1,558
1,676
1,696
Accounts Receivable, Net
2,351
2,212
2,010
Inventories
1,321
1,351
1,309
Total Current Liabilities
1,220
1,319
1,124
Payables & Accruals
- -
- -
- -
ST Debt
180
147
139
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,463
1,533
1,445
1,342
5,783
2025
1,393
1,402
- -
- -
- -
2026
1,130
1,058
918
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.03
0.01
-0.05
0.01
2025
0.02
0.01
- -
- -
- -
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
0.01
- -
0.06
2025
- -
0.03
- -
- -
- -
2026
- -
- -
0.01
- -
- -

Company Description

CEO
Wu Jun Lan
Full Time Employees
4,852
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building B01, Entrepreneurial Headquarters Base Tianjin TI China 301700
IPO Date
Nov 3, 2009
Business
Tianjin Chase Sun Pharmaceutical Co.,Ltd Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) is a China-based company principally engaged in the research, development, production, and sale of pharmaceutical products and medical devices; its core offerings include traditional Chinese medicine formula granules, finished drugs such as blood purification injections, moxifloxacin hydrochloride injections (Anrotai), and low molecular weight heparin calcium injections (Bopuqing), raw pharmaceutical materials and excipients, medical devices, medical and health services, and smart supply chain solutions for pharmaceuticals and devices. The company operates primarily in China with a focus on therapeutic areas including immunity, cardiovascular and cerebrovascular diseases, respiratory system conditions, neurodegenerative diseases, anti-tumor treatments, sepsis, pulmonary hypertension, and infectious diseases; it maintains production facilities compliant with GMP standards for bulk drugs, capsules, granules, injections, and technology transfer services. Founded in 1996 and headquartered in Tianjin, China, the company listed on the Shenzhen Stock Exchange's GEM board in 2009 as a state-owned enterprise under local asset administration; it recently advanced clinical research on Xuebijing Injection for sepsis treatment published in eClinicalMedicine, participated in the 10th Smart Pharmaceutical Conference issuing the Tianjin Initiative on digitalization, joined the pharmaceutical industry new quality productive forces innovation community, and pursued strategic partnerships for market expansion while canceling a planned acquisition of additional stake in Hubei Enoray Biopharmaceutical.